Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities

NCT04525300 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Obesity

Interventions

DRUG: Liraglutide
DRUG: placebo

Sponsor

Xiangya Hospital of Central South University